Most Americans Support Progressive Tobacco Sales Ban: CDC Study

Feb.03.2023
Most Americans Support Progressive Tobacco Sales Ban: CDC Study
A recent study by the CDC found that most Americans support gradually phasing out the sale of all tobacco products.

A new study by the Smoking and Health Office of the US Centers for Disease Control and Prevention (CDC) shows that most Americans support a gradual phasing out of the sale of all tobacco products.


According to data from an online survey of American adults aged 18 or older in 2021 (N=6,455),...


A policy to ban the sale of menthol cigarettes is supported by 62.3% of adults, according to a CDC research report. The report also notes that roughly two-thirds of respondents who currently do not use tobacco products and more than one-third of those who currently use tobacco products (including menthol cigarettes) support the policy.


A policy to ban the sale of all tobacco products is supported by 57.3% of adults, according to a research brief. The brief clarifies that over 61% of respondents who do not currently use tobacco products and approximately one-fourth of those who currently use tobacco products support this policy.


Laurent Huber, director of the Health and Action on Smoking and Health (ASH), stated that his organization welcomes the strong support of Americans who recognize the deadly and unnecessary losses caused by tobacco products to our families, communities, and nation. He also called for the advancement of global tobacco endgame policies.


Cigarettes are the only consumer product that is deadly when used exactly as intended by the manufacturer - they cause widespread harm and death without the need for misuse or excessive use. Allowing the sale of tobacco products has no benefit to our society, and more jurisdictions are taking action to remove them from store shelves.


The policy of gradually stopping tobacco sales, commonly referred to as tobacco endgame, can take on many forms, including:


Reducing the nicotine content in cigarettes to a non-addictive level, similar to what is being done in New Zealand and explored by the US FDA.


It is proposed to prohibit the sale of tobacco to anyone born after a certain date, effectively raising the age for purchasing tobacco products by one year annually, as has been done in New Zealand and Brookline, Massachusetts (commonly referred to as the tobacco or smoke-free generation).


Gradually phasing out tobacco retail licenses.


The use of filter tips in cigarettes is being banned, just as ASH and its partners are working towards achieving through the UN plastic pollution treaty currently under negotiation this year.


According to Laurent Huber of ASH, political will is often the reason for delays in tobacco control policy implementation. However, there is strong scientific evidence to support such policies and the public is also strongly in favor, as demonstrated by the Centers for Disease Control and Prevention.


ASH is encouraging more jurisdictions to follow the lead of Beverly Hills and Manhattan Beach in California and gradually cease the sale of tobacco products, prioritizing citizens' health.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13
Charlie’s Plans Q3 2026 Pilot of America’s First Age-Gated Flavored Disposable Vape
Charlie’s Plans Q3 2026 Pilot of America’s First Age-Gated Flavored Disposable Vape
U.S. vape company Charlie’s Holdings announced plans to pilot its age-gated flavored disposable vape products in hundreds of retail stores during the third quarter of 2026. The company said the products will utilize AI- and blockchain-powered age-verification technology designed to address FDA concerns over youth access and potentially create a new compliance pathway for flavored vape products.
Jun.15
Trump’s Tobacco Investments and Industry Donations Draw Scrutiny as FDA Eases Vape and Nicotine Pouch Rules
Trump’s Tobacco Investments and Industry Donations Draw Scrutiny as FDA Eases Vape and Nicotine Pouch Rules
A report by KFF Health News says that as the Trump administration pursued a series of policies favorable to the nicotine and tobacco industry, President Donald Trump increased his holdings in tobacco companies while benefiting from substantial industry-linked political donations, prompting questions from public health advocates about potential conflicts of interest and regulatory direction.
Jun.12
Scotland Plans to Remove Business Rates Relief From Vape Shops From 2027
Scotland Plans to Remove Business Rates Relief From Vape Shops From 2027
The Scottish Government plans to remove business rates relief from vape shops from April 1, 2027, saying the measure is intended to ensure vape retailers contribute to the high street and align rates relief with public health commitments, while the impact on convenience stores that sell vaping products remains unclear.
News
Jun.26 by 2Firsts Perspectives
 NYT: Reynolds American Donated $5 Million Before FDA Vape Policy Shift
NYT: Reynolds American Donated $5 Million Before FDA Vape Policy Shift
According to The New York Times, Reynolds American donated $5 million to a Trump-backed super PAC shortly before the FDA introduced a new policy that could benefit major tobacco companies seeking to sell flavored vaping products.
News
May.21
From myblu to Zone: Imperial Brands Refocuses NGP Strategy in HY26
From myblu to Zone: Imperial Brands Refocuses NGP Strategy in HY26
mperial Brands’ HY26 results point to a more selective NGP transition. The company is using cash flow from traditional tobacco to fund targeted investments in modern oral nicotine, heated tobacco and reusable vaping systems. Its decision to exit the legacy myblu vaping business in the U.S., while expanding Zone nicotine pouches. In Europe, Imperial’s NGP growth is being driven by a multi-category portfolio including blu, Pulze and Zone/Skruf.
Special Report
May.12